Ipamorelin vs HGH (Somatropin)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: Somatropin, Human Growth Hormone
Human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. It is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. Almost everything you read about HGH for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used.
Key Comparison Insights
- HGH (Somatropin) is FDA approved, while Ipamorelin remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- HGH (Somatropin) has stronger research evidence (FDA Approved) compared to Ipamorelin (Human Trials).
Detailed Comparison
| Attribute | Ipamorelin | HGH (Somatropin) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | HGH binds the growth hormone receptor, mostly in the liver, which triggers IGF-1 release. IGF-1 does much of the work people associate with growth hormone: it drives cell growth, protein synthesis and cartilage growth. HGH itself acts directly on fat tissue, encouraging lipolysis, and it opposes insulin, which is why higher doses push blood sugar up and can create insulin resistance over time. The direct-versus-IGF-1 split matters practically: effects on fat come quickly and are largely direct, while effects on muscle and connective tissue are slower and IGF-1 mediated. This is also why HGH and IGF-1 LR3 are not interchangeable despite being linked. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 0.15-0.3 mg daily (clinical) or 2-4 IU daily (community) Once daily, typically evening |
| Administration | Subcutaneous injection | Subcutaneous injection, usually daily, commonly in the evening to mimic natural nocturnal release |
| Typical Duration | 8-12 weeks typical | Clinical use is ongoing and monitored. Community cycles are typically reported as 3-6 months. |
| Best Time to Take | Before bed or morning (fasted) | Evening, before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | For diagnosed growth hormone deficiency the evidence is solid and decades deep: recombinant HGH restores body composition, bone density and quality of life in adults with genuine deficiency, and it is approved for that. For everyone else the picture is far weaker. The famous Rudman study in the New England Journal of Medicine in 1990 gave HGH to 12 older men for six months and reported gains in lean mass and reductions in fat, and that single small trial launched an entire anti-aging industry. It had no functional strength or performance endpoints, it was not designed to assess safety, and Rudman maintained until his death in 1994 that it carried no anti-aging implications. NEJM published an editorial in 2003 criticizing the industry that had grown up around citing it. Subsequent reviews of HGH in healthy older adults have found modest body composition changes alongside frequent side effects, with no demonstrated benefit to strength, function or longevity. Long-term supraphysiologic use carries real risks including insulin resistance and, at sustained high doses, acromegaly-like changes. |
Frequently Asked Questions: Ipamorelin vs HGH (Somatropin)
What is the difference between Ipamorelin and HGH (Somatropin)?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. HGH (Somatropin) is a growth hormone peptide that human growth hormone is the real thing rather than a secretagogue: a 191-amino-acid protein identical to what your pituitary makes, produced recombinantly since the 1980s. it is a properly approved medicine for growth hormone deficiency, and it is also the most misused compound in this entire space. almost everything you read about hgh for anti-aging or physique traces back to a single small 1990 study whose own author later disowned how it was used. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or HGH (Somatropin)?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while HGH (Somatropin) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and HGH (Somatropin) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and HGH (Somatropin) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.